

(10) International Publication Number
WO 2016/205721 A1(43) International Publication Date
22 December 2016 (22.12.2016)

(51) International Patent Classification:

A61K 47/48 (2006.01) A61K 31/57 (2006.01)

(21) International Application Number:

PCT/US2016/038195

(22) International Filing Date:

17 June 2016 (17.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/181,550 18 June 2015 (18.06.2015) US

(71) Applicant: SAGE THERAPEUTICS, INC. [US/US];
215 First Street, Cambridge, MA 02142 (US).(72) Inventors: SALITURO, Francesco, G.; 25 Baker Drive,
Marlborough, MA 01752 (US). ROBICHAUD, Albert,
Jean; 2 Earhart St., 915, Cambridge, MA 02141 (US).
WATSON, Paul; 104 Gateridge Place, Carrboro, NC
27510 (US). HUNKE, William; 505 Sweetshire Court,
Middletown, DE 19079 (US).(74) Agent: YEE, Dominic, Jason; Lando & Anastasi, LLP,
Riverfront Office Park, One Main Street, Suite 1100, Cam-
bridge, MA 02142 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE




Figure 1

(57) Abstract: Provided herein are pharma-
ceutically acceptable aqueous solution
comprising a neuroactive steroid, a
sulfobutyl ether beta cyclodextrin and a
buffer; wherein: the solution is a stable
solution between a pH of about 3 and about
9, e.g., at room temperature, for at least 1,
2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12 months; 1, 2, 3 years or more; the
buffer is present at a concentration of at
least 0.1 mM; or the solution remains sub-
stantially free of impurities (e.g., the solu-
tion is substantially free of impurities at
room temperature for at least 1, 2, 3, 4
weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
months; 1, 2, 3 years or more).



— as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

Published:

— with international search report (Art. 21(3))